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Clinical application of antimicrobial peptides (AMPs), as with conventional antibiotics,
may be compromised by the development of bacterial resistance. This study
investigated AMP resistance in methicillin resistant Staphylococcus aureus, including
aspects related to the resilience of the resistant bacteria toward the peptides, the
stability of resistance when selection pressures are removed, and whether resistance
can be overcome by using the peptides with other membrane-permeabilising agents.
Genotypically variant strains of S. aureus became equally resistant to the antibacterial
peptides melittin and bac8c when grown in sub-lethal concentrations. Subculture
of a melittin-resistant strain without melittin for 8 days lowered the minimal lethal
concentration of the peptide from 170 µg ml−1 to 30 µg ml−1. Growth for 24 h in
12 µg ml−1 melittin restored the MLC to 100 µg ml−1. Flow cytometry analysis of
cationic fluorophore binding to melittin-naïve and melittin-resistant bacteria revealed
that resistance coincided with decreased binding of cationic molecules, suggesting
a reduction in nett negative charge on the membrane. Melittin was haemolytic at
low concentrations but the truncated analog of melittin, mel12−26, was confirmed
to lack haemolytic activity. Although a previous report found that mel12−26 retained
full bactericidal activity, we found it to lack significant activity when added to culture
medium. However, electroporation in the presence of 50 µg ml−1 of mel12−26,
killed 99.3% of the bacteria. Similarly, using a low concentration of the non-ionic
detergent Triton X-100 to permeabilize bacteria to mel12−26 markedly increased its
bactericidal activity. The observation that bactericidal activity of the non-membranolytic
peptide mel12−26 was enhanced when the bacterial membrane was permeablized
by detergents or electroporation, suggests that its principal mechanism in reducing
bacterial survival may be through interaction with intracellular organelles or processes.
Additionally, our results showed that the haemolytic peptide bac8c, had increased
antibacterial activity at non-haemolytic concentrations when used with membrane-
permeabilizing surfactants.
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INTRODUCTION
Antimicrobial peptides (AMPs) have been proposed as possible
additions to, or replacements for, conventional antibiotics which
are declining in efficacy due to increasing resistance among
clinically important pathogenic bacteria (Yeaman and Yount,
2003; Reddy et al., 2004). They are generally amphipathic protein
molecules of approximately 8−50 amino acids, usually have a net
positive charge and contain a high proportion of hydrophobic
residues (Yeaman and Yount, 2003; Reddy et al., 2004). AMPs
appear to be a significant part of the innate immune system of
many organisms, causing non-specific inhibition or destruction
of bacterial pathogens, which appears to be mediated by peptides
binding to anionic groups on the cell surface and interacting
hydrophobically with membranes to form lethal pores (Gordon
et al., 2005). Targeting the fundamental anionic and hydrophobic
regions of bacterial membranes has been suggested to make
the development of resistance toward cationic peptides unlikely,
requiring significant alteration to the physiology of the cell
(Gordon et al., 2005; Seo et al., 2012; Gaspar et al., 2013).
Nevertheless, pathogens have been regularly exposed to AMPs
and resistance or avoidance mechanisms have been described
(Gordon et al., 2005; Wiesner and Vilcinskas, 2010).
Although there have been studies into how pathogens may
develop resistance to AMPs (Andrä et al., 2011; Askoura et al.,
2011; Guilhelmelli et al., 2013), it remains unclear how significant
the development of resistance may be for the clinical use of
AMP-based therapies. Also, some AMPs have intracellular targets
that may be more important for killing the pathogen than
membrane disruption (Laverty et al., 2011). The declining efficacy
of antibiotics provides a strong incentive to understand how
AMPs might be applied for therapeutic purposes, but there are
still gaps in our understanding of which peptides may have
intracellular antibacterial activity and how they may be delivered
to the bacterial cytoplasm.
We selected the bactericidal peptides melittin, isolated from
honey bee venom (Kreil and Bachmayer, 1971; Raghuraman
and Chattopadhyay, 2007), and bac8c, a truncated and modified
analog of bovine neutrophil peptide (Spindler et al., 2011), as
model peptides to test the kinetics of resistance development, the
resilience of the resistant state, and whether bacterial resistance
might be defeated in clinical treatment. In common with some
other antibacterial peptides, the haemolytic capability of melittin
may preclude its clinical use (Asthana et al., 2004; Raghuraman
and Chattopadhyay, 2007). However, a sub-fragment containing
residues 12−26 of melittin has been reported to maintain
antibacterial activity with considerably reduced haemolytic
capability (Yan et al., 2003). We investigated the potential for
transporting melittin, mel12−26, or bac8c into MRSA to increase
their bactericidal efficacy.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
Staphylococcus aureus strains were provided by the Australian
Collaborating Centre for Enterococcus and Staphylococcus Species
typing and research (ACCESS), Faculty of Health Sciences,
School of Biomedical Sciences, Curtin University, Perth, WA,
Australia. The S. aureus strains used in this study were: Aus3: a
mercuric acetate and mercuric chloride-resistant clone of ST239-
MRSA-III (Coombs et al., 2007), Bengal bay (BB): origin ST772-
MRSA-V (Coombs G. et al., 2012), and WBG 8287: genetic
lineage ST1-IVa (Coombs et al., 2007) and a methicillin sensitive
S. aureus strain W17S: lineage ST93-MSSA (Coombs G.W. et al.,
2012). Bacteria were grown in 25 g l−1 bactopeptone medium
(Oxoid, Basingstoke, Hants, UK), pH 7.4 and incubated at 37◦C
with orbital shaking at 200 rpm. Bactopeptone medium was
selected as a growth and test medium because it showed less
inhibitory effect on the antimicrobial activity of the peptides
than the more commonly used complex and nutrient-rich
media we tested (data not shown). A relatively simple and
dilute medium was believed to be appropriate because clinical
treatment of topical infections would be expected to include
initial cleansing of the infected region with dilute solutions
prior to the application of antimicrobial agents, to maximize
antibacterial function.
Antibacterial Peptides and Measurement
of Minimal Lethal Concentrations
Bac8c (RIWVIWRR-OH), melittin (GIGAVLKVLTTGLPALIS
WIKRKRQQ-OH) and its sub-fragment mel12−26 (bold type)
were in L-isomer form and 95% pure by mass spectrometry
(Mimotopes, Melbourne, VIC, Australia). Peptides were
dissolved in molecular biology grade water and tested for their
minimal lethal concentration (MLC) against S. aureus strains,
using a variation of a previously described method (Dean et al.,
2011). Briefly, 200-µl aliquots of bacterial culture (106 CFU
ml−1 in 8 g l−1 bactopeptone) were transferred to a polystyrene
96-well plate (Nunc, New York, USA) containing the test
peptides at final concentrations from 1 to 170 µg ml−1. The
plates were incubated at 37◦C with 200 rpm orbital shaking
for 1 h, then bacteria from each well were plated on separate
1.5% agar plates, containing 25 g l−1 bactopeptone medium,
and incubated at 37◦C for 24 h. Survival was measured by
colony numbers, as a percentage of untreated controls. Negative
controls contained mock-inoculated medium. The lowest dose
that resulted in >99.9% cell death was recorded as the MLC.
Experiments were repeated two or three times, each with
triplicate samples.
Growth in Sub-inhibitory Doses of
Melittin and Bac8c
Strains WBG 8287, W17S, Aus3, and BB were suspended at 107
CFU ml−1 in 200 µl of 8 g l−1 bactopeptone broth, containing
2.5 µg ml−1 of melittin, and incubated for 12 h at 37◦C with
150 rpm orbital shaking. Bacteria were counted and resuspended
at 107 CFU ml−1 in 200 µl of 8 g l−1 bactopeptone medium,
containing 5 µg ml−1 melittin, and incubated for an additional
12 h. This was followed by subculture at six 12 h intervals, with
melittin at 8, 10, 15, 20, 40, and 60 µg ml−1, respectively, and
six more subcultures at 12 h intervals with 80 µg ml−1 melittin.
Parallel experiments were performed with bac8c concentrations
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increasing from 2µg ml−1 to 180µg ml−1, for strains WBG 8287,
W17S, and Aus3.
Scanning Electron Microscopy of
Bacteria Exposed to Melittin
Wild-type and melittin-resistant WBG 8287 were washed in
1 ml PBS (106 CFU ml−1) and centrifuged at 12,000 × g
for 5 min. The bacterial pellets were resuspended in 1 ml
PBS, re-centrifuged, and suspended in 100 µl PBS containing
10 µg ml−1 of melittin for 1 h at 37◦C with 200 rpm orbital
shaking. Control samples were prepared by the same procedure,
without melittin. Aliquots of each bacterial suspension (15 µl)
were dispensed onto separate aluminum stubs and incubated
for 30 min at 37◦C. The bacteria were fixed by overlaying
with 2.5% glutaraldehyde (Asia Pacific Specialty Chemicals
Limited, Sydney, NSW, Australia) for 3 h at room temperature.
The stubs were washed by gently applying high-purity water
to the tilted surface, followed by sequential immersion for
30 min at 37◦C in 70, 90, and 100% ethanol, respectively.
The samples were dried in a desiccator for 24 h at 37◦C
over silica gel. The stubs were evaporatively coated with a
3 nm layer of platinum and viewed using a Zeiss Neon 40ESB
Crossbeam scanning electron microscope (SEM: Sydney, NSW,
Australia).
Measurement of Cationic Fluorophore
Binding to the MRSA Outer Surface, by
Flow Cytometry
Wild-type and melittin-resistant WBG 8287 (107 CFU ml−1)
were washed twice in 1 ml phosphate buffer (PB) with
centrifugation at 8,000 × g for 5 min and were resuspended
in 1 ml of PB. A 100 µl aliquot of bacterial suspension was
added to 400 µl of HpH2O (5 × 106 CFU ml−1) containing
2.08 picomoles of the cationic fluorescent probe Bacterisense
645 (Perkin Elmer, Melbourne, VIC, Australia). The bacteria
were then washed three times for 10 min each in PB, with
shaking at room temperature and centrifugation, to remove
unbound or weakly bound probe. Dye-binding to bacteria was
measured using an Attune Acoustic Focusing Cytometer (Life
Technologies, Melbourne, VIC, Australia) with Attune focusing
fluid. For these experiments, all solutions including growth media
were filtered through 0.2 µm membrane filters.
Removal and Return of Melittin Selection
Melittin-resistant bacteria (WBG 8287) were subcultured daily
for 7 days in bactopeptone medium without melittin. Their
survival after exposure to 0, 3, 6, or 12 µg ml−1 melittin in
8 g l−1 bactopeptone medium for 1 h was measured daily. After
seven days of melittin-free growth, the MLC of melittin was
measured, the bacteria were returned to medium containing
12 µg ml−1 melittin for 24 h and the MLC was measured
again.
Preparation of Electro-Competent MRSA
Wild-type and melittin-resistant WBG 8287 (109 CFU ml−1
in 1 ml PBS) were centrifuged at 8,000 × g for 10 min,
washed with 500 mM sucrose, recentrifuged and resuspended in
500 µl of 500 mM sucrose. The bacteria were chilled on ice for
30 min, recentrifuged and resuspended in 500 µl of 500 mM
sucrose with 15% glycerol and stored at −80◦C. For use in
electroporation experiments, frozen stocks were thawed at room
temperature.
Electroporation of MRSA with AMPs
Electro-competent wild-type WBG 8287 were placed in
electroporation cuvettes (Gene pulserTM Bio-rad, Sydney,
NSW, Australia) with a 0.1 cm electrode gap, with melittin
(2.5 µg ml−1) or without melittin (controls) and cuvettes
were chilled on ice for 1 min. Bacteria were pulsed for 2.5 ms
using a Micropulser electroporator (Bio-rad, Sydney, NSW,
Australia) set at 25 µF capacitance, 2.5 kV and 100  by-pass
resistance. Immediately after electroporation, melittin was added
to control samples at 2.5 µg ml−1 and 450 µl of 500 mM
sucrose solution was added to all cuvettes. Bacterial suspensions
were placed on ice for 15 min, spread on bactopeptone agar
plates and incubated for 24 h at 37◦C. Survival was measured
by colony numbers as a percentage of a melittin negative,
non-electroporated control. The same method was used to
insert mel12−26 (50 µg ml−1) or bac8c (2 µg ml−1) into
wild-type bacteria, and melittin (10 µg ml−1) or mel12−26
(50 µg ml−1) into melittin-resistant WBG 8287. Electroporation
experiments were repeated three times, each with four replicates
per peptide.
Isolation of Human Erythrocytes and
Haemolysis Assay
Whole blood (15 ml) was drawn from the vein of a 26 year
old male volunteer and stored in an EDTA-coated Vacutainer
(BD Biosciences, Adelaide, SA, Australia). Erythrocytes were
separated by centrifuging at 500 × g for 5 min at 4◦C. The
supernatant was removed and erythrocytes were washed with
10 ml of ice-cold PBS and recentrifuged. Two otherwise identical
sample groups were prepared by removing the supernatant
and resuspending the erythrocytes in 10 ml PBS at 106
cells ml−1, either with or without 0.005% v/v Triton X-100
(Ajax, Perth, WA, Australia). Melittin (5 µg ml−1), mel12−26
(130 µg ml−1) or bac8c (6 µg ml−1) was added to triplicate
samples of PBS samples with no Triton X-100, and 2.5 µg
ml−1 melittin, 80 µg ml−1 mel12−26, and 4 µg ml−1 bac8c
were added to PBS samples with Triton X-100. Triton X100
was added to erythrocyte suspensions at a concentration of
1% v/v as a positive control for haemolysis. All test and
control samples were incubated at 37◦C for 30 min with
150 rpm orbital shaking, then sedimented at 500 × g. The
extent of haemolysis was measured by the absorbance of the
supernatant at 405 nm, using a Victor Multilabel plate reader
spectrophotometer.
Statistics
Data compared between parental and resistant bacterial
populations were analyzed by the paired t-test using Microsoft
Excel software.
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RESULTS
Minimum Inhibitory Concentration and
Minimum Lethal Concentrations of AMPs
for S. aureus
Table 1 shows the MLC of antibacterial peptides for different
S. aureus strains. The MIC and MLC of mel12−26 could not
be determined because the concentrations required were beyond
the solubility limit of the peptide in bactopeptone medium.
Above 50 µg ml−1 the excess peptide remained as a cloudy and
sedimentable suspension. The MLC of bac8c differed significantly
in strain WGB 8287 (7 µg ml−1) from that of both W17S and
Aus3 (both 80 µg ml−1).
After 14 sub-cultures at 12 h intervals, in bactopeptone
medium containing sub-inhibitory concentrations of melittin,
the MLC for WBG 8287, W17S, Aus3, and BB was increased
30−34 fold (Table 2). While growth for 14 sub-cultures in the
presence of bac8c increased the MLC of the peptide 23-fold
for WBG 8287, only a twofold increase was required to reach
similar levels of resistance in the naturally more resistant strains
W17S and Aus3 (Table 2). The MLC for resistant WBG 8287 in
bactopeptone broth was 170 µg ml−1, but in phosphate buffer
was only 3 µg ml−1. The addition of NaCl at 8 and 15 g l−1
increased the MLC in phosphate buffer to 5 and 7 µg ml−1,
respectively (Table 2), suggesting that salt concentration plays
only a minimal role in peptide resistance.
TABLE 1 | Minimum lethal concentration of melittin, mel12−26, and bac8c
for MRSA strains in bactopeptone media.
Peptide MRSA strain MLC (µg ml−1)
Melittin WBG 8287 5
W17S 5
Aus3 5
BB 5
Mel12−26 WBG 8287 >130a
Bac8c WBG 8287 7
W17S 80
Aus3 80
aMinimal lethal concentration (MLC) exceeded the highest concentration tested.
TABLE 2 | Minimal lethal concentration (MLC) of melittin and bac8c
against MRSA in different media, following induced resistance to the
peptides in bactopeptone medium.
MRSAStrain Culture medium Melittin MLC
(µg ml−1)
Bac8c MLC
(µg ml−1)
WBG 8287 Bactopeptone 170 160
PBa 3 ND
PB + 8 g l−1 NaCl 5 ND
PB + 15 g l−1 NaCl 7 ND
W17S Bactopeptone 150 170
Aus3 Bactopeptone 160 150
BB Bactopeptone 150 ND
aPhosphate buffer; ND, not determined.
Structural Appearance of WBG 8287
after AMP Exposure
Scanning electron micrographs of control samples showed a
rippled surface topography, which we interpret as showing the
surface of the thin platinum coating over the peptidoglycan
matrix of the cell wall (Figures 1A,B). Predictably, the
development of melittin resistance caused no discernable changes
in the external appearance of the cell wall (Figures 1E,F). After
exposure to 10 µg ml−1 of melittin for 1h, wild-type strains
showed major structural changes (Figures 1C,D) ranging from
protrusions or “blebs” on the outer surface to the collapse of
cellular structure. Under the same conditions, melittin-resistant
WBG 8287 showed occasional surface blebs, but none displayed
major loss of structural integrity (Figures 1G,H).
Binding of Bacterisense 645 to Wild-type
and Melittin-Resistant MRSA
The mean fluorescent intensity emitted from the cationic
probe Bacterisense 645, bound to the surface of wildtype and
FIGURE 1 | Scanning electron microscopy images of melittin naïve and
resistant MRSA. (A,B) Untreated parental strain, (E,F) untreated
melittin-resistant strain, (C,D) parental strain exposed to 10 µg ml−1 melittin.
(G,H) Resistant strain exposed to 10 µg ml−1 melittin.
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FIGURE 2 | Flow cytometry analysis of fluorescent probe binding to
MRSA. Fluorescence intensity of cationic fluorophore Bacterisense 645
bound to parental strain WBG 8287 (closed plot area) and melittin-resistant
WBG 8287 (open plot area). Data represent the mean of three tests.
melittin resistant strains totalled 34099 and 6445, respectively
(P < 0.001; Figure 2) suggesting that the negative charge
responsible for binding the cationic fluorophore to the outer
surface of melittin-resistant bacteria was only 19% of that
present on the outer surface of the melittin-sensitive parental
strain.
Removal and Return of Melittin Selection
One hundred percent of melittin-resistant WBG 8287 survived
when exposed to 3 µg ml−1 melittin in bactopeptone medium
for 1 h. However, after growth for 24 h in bactopeptone
medium without melittin, only 46% survived the same treatment.
(P < 0.001; Figure 3). Eight daily subcultures without melittin,
reduced the MLC of melittin from 170 µg ml−1 to 30 µg ml−1
(Table 3). However, a single 24 h culture of this resensitized
population, in 12 µg ml−1 of melittin, raised the MLC to 100 µg
ml−1: i.e., 58.8% of that seen in the most resistant population
(Table 3).
Electroporation of MRSA in the Presence
of AMPs
WBG 8287 electroporated in 500 mM sucrose showed
78% survival, compared to mock-electroporated controls.
Electroporation in the presence of antibacterial peptides
resulted in significantly greater cell death than simple exposure
to the same peptide concentration. Electroporation with
melittin (2.5 µg ml−1) or mel12−26 (50 µg ml−1) reduced
the number of surviving colonies to 75 and 21% of non-
electroporated controls controls, respectively (P < 0.05;
Figures 4A–C). Survival of control group bacteria, exposed to
bac8c immediately after electroporation, was highly variable;
with results falling outside the test required for significance
(P = 0.053). Electroporation of melittin-resistant bacteria in the
FIGURE 3 | Survival of melittin-resistant bacteria cultured with or
without melittin for 7 days. (A) Survival of parental WBG 8287 as a
percentage of untreated controls, after exposure to melittin at 3 µg ml−1
(open circles), 6 µg ml−1 (closed circles), and 12 µg ml−1 (open squares) on
days 0, 1, 4, and 7, respectively. (B) Survival of melittin resistant WBG 8287,
maintained in medium containing 12 µg ml−1 melittin. Data represent
combined results of two experiments with three replicates per experiment,
Error bars represent standard deviation.
TABLE 3 | Minimum lethal concentrations of antimicrobial peptides (AMPs)
for resistant WBG 8287 and reversion/recovery populations.
Population MLC µg ml−1
Melittin-resistant 170
Melittin-reversion 30
Melittin-recovery 100
Bac8c-resistant 160
Bac8c-reversion 110
presence of 10 µg ml−1 of melittin (Figure 4D) or 50 µg ml−1
mel12−26 (Figure 4E) reduced survival to 41 and 52% of control
values, respectively.
Effects of Triton X-100 on AMP Activity
The survival of wild-type WBG 8287 exposed to mel12−26
decreased as the Triton X-100 concentration increased
(Figure 5). The MLC of melittin (5.0 µg ml−1) decreased
to 3.5 and 2.75 µg ml−1 in the presence of 0.005 and 0.1%
Triton X-100, respectively (Table 4). In medium with 0.005 or
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FIGURE 4 | Electroporation of MRSA with antimicrobial Peptides (AMPs). Electrocompetent WBG 8287 cells suspended in (A) 2.5 µg ml−1 melittin, (B)
50 µg ml−1 mel12−26, and (C) 2 µg ml−1 bac8c and electroporated immediately (EP). Melittin-resistant WBG 8287 suspended in (D) 10 µg ml−1 melittin or (E)
50 µg ml−1 mel12−26 and electroporated. Survival was measured as a percentage of zero peptide, unelectroporated controls. Data represent the mean of six
samples and error bars represent standard deviation. ∗P ≤ 0.05; ∗∗P ≤ 0.001.
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FIGURE 5 | Survival of WBG 8287 exposed to 5 µg ml−1 mel12−26 with
increasing concentrations of Triton X-100. Data represent the mean of
three tests and error bars show standard deviation.
0.1% Triton X-100, the MLC of mel12−26 was 80 and 25 µg
ml−1, respectively (Table 4). Similarly, increasing Triton X-100
concentration from 0.005 to 0.1% reduced the MLC of bac8c
from 4.7 to 2.6 µg ml−1 (Table 4).
The MLC of melittin or mel12−26 against melittin-resistant
WBG 8287, W17S, and Aus3 bacteria was not affected by the
presence of Triton X-100 at the non-haemolytic concentration of
0.005%.
Haemolysis by Triton X-100 in
Combination with AMPs
In PBS, 5µg ml−1 of melittin showed substantial erythrocyte lysis
with or without 0.005% Triton X-100 (Figure 6). Suspension of
erythrocytes in PBS plus 0.005% Triton X-100 (A405 = 6.4% of
total lysis) differed only marginally from suspension in PBS alone
(A405 = 5.1% of total lysis).
DISCUSSION
The rapidity with which resistance to melittin or bac8c is
initiated and enhanced suggests that resistance mechanisms pre-
exist within populations of S. aureus. The use of AMPs as
antimicrobial agents could be impaired by the rapid development
of resistant populations and further complicated by the effect of
salts and exogenous proteins in reducing peptide toxicity (Lee
et al., 1997; Hancock, 2000; Gordon et al., 2005; Brogden and
Brogden, 2011; Lofton et al., 2013).
Scanning electron microscopy confirmed that resistant
bacteria were visibly less damaged by exposure to melittin than
the parental strain, as predicted from their enhanced survival.
Nevertheless, protruding vesicles, or “blebs”, observed in this and
previous studies (Hartmann et al., 2010), were visible on the
surface of some resistant cells, suggesting that melittin resistance
TABLE 4 | Minimum lethal concentration of AMPs against WBG 8287 in
bactopeptone with Triton X-100.
Peptide BPa (µg ml−1) BP + 0.005%
TX-100b (µg
ml−1)
BP + 0.1%
TX-100 (µg ml−1)
Melittin 5 3.5 ± 0.55 2.75 ± 0.27
Mel12−26 >130 80 ± 0.00 25 ± 0.00
Bac8c 7 4.7 ± 0.52 2.6 ± 0.49
a8 g l–1 bactopeptone; bTriton X-100.
is manifested as a reduced degree of damage, rather than an
all or none protection. Within the parental population, a very
small proportion of cells showed less structural damage than the
majority, suggesting that this resistant sub-group may restore
and maintain population numbers during exposure to high
concentrations of melittin.
On withdrawal of melittin from cultures, resistance declined
rapidly but not completely. This differed from a previous
study (Perron et al., 2006), which reported that resistance in
Pseudomonas fluorescens and E. coli to pexiganan, an analog of
magainin peptides from the skin of the African clawed frog,
remained stable over 4 days without selective pressure. The
rapid decline of resistance to melittin suggests that maintaining
resistance may impose an increased metabolic demand. Some
antibiotic and AMP-resistant bacteria have slower generation
rates than wild-type bacteria or are unable to grow on nutrient
depleted media (Lofton et al., 2013), which may represent the
metabolic cost of resources used in developing and maintaining
resistance to antimicrobial agents (Andersson and Hughes,
2010). However, multiple studies have shown some antibiotic-
resistant bacteria have increased growth rates over their parental
population in certain media (Björkman et al., 2000; Nagaev
et al., 2001; Yu et al., 2005; Andersson and Hughes, 2010), and
resistant bacteria can persist in patients as long as 1–4 years
after treatment (Sjolund et al., 2003; Maria et al., 2005). This
casts doubt on whether the metabolic cost of resistance must
eventually cause a reversion of the population to its wild-type in
every case, when selection pressures are removed. However, our
study clearly observed reversion to relative peptide-sensitivity in
these S. aureus strains.
Consistent with previous findings (Ouhara et al., 2008; Andrä
et al., 2011), increased tolerance to melittin was attributable at
least partly to a reduction in negative-charge density on the
outer bacterial surface. It has been suggested that decreased
affinity of cationic molecules for the bacterial outer membrane
results in nature from aminoacylation of negatively charged
phospholipid head-groups with cationic amino acids (Andrä
et al., 2011). This hypothesis is consistent with a reduction in the
outer membrane negative charge on peptide-resistant bacteria,
as suggested by the reduced binding of the cationic probe
Bacterisense 645. A proportion of the wild-type and resistant
population appeared to overlap in the measured fluorescent
intensity created by the binding of Bacterisense 645. Consistent
with observations from the resistance-reversion experiments,
this supports the proposal that the MRSA population maintains
a range of levels of anionic surface charge. Since the starting
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FIGURE 6 | Hemolysis by antibacterial peptides with Triton X-100.
Release of hemoglobin into the supernatant in (A) PBS with: melittin 5 µg
ml−1, mel12−26 130 µg ml−1, or bac8c 6 µg ml−1. (B) PBS plus 0.005%
Triton X-100 with: melittin 2.5 µg ml−1, mel12−26 80 µg ml−1, or bac8c
4 µg ml−1. Data represent the mean of three samples and error bars
represent standard deviation.
cultures have no known prior exposure to AMPs, it appears
that this may be an intrinsic population safety measure against
cationic toxins encountered in nature. Likewise, it may be
beneficial for population growth that not all of the bacteria
in the resistant population keep their anionic charge-masking
modifications, due to the increased metabolic demand of the
process.
Melittin, mel12−26, and the unrelated peptide bac8c,
showed increased bactericidal activity when inserted into
WBG 8287 by electroporation. This was concluded to
result from internalization of the peptides, rather than from
membrane damage caused by electroporation, because controls
electroporated without peptides showed significantly higher
survival rates in every case. Control bacterial suspensions to
which peptides were added immediately after electroporation
showed significantly higher survival rates than those exposed
to the peptides during electroporation. In contrast to an earlier
report (Yan et al., 2003), in our hands the melittin sub-fragment
mel12−26 showed low external toxicity to S. aureus, and the
susceptibility levels observed more closely match those reported
by Subbalakshmi et al. (1999). However, when transported into
the cell by electroporation, mel12−26 showed a fourfold increase
in antibacterial activity. Other studies (Asthana et al., 2004;
Pandey et al., 2011) have suggested that the leucine zipper motif
of melittin and similar peptides promotes dimerization and
secondary structure formation. Truncating melittin, to retain
only amino acids 12−26, removed the leucine zipper sequence
and reduced its haemolytic capability. The absence of the zipper
motif also significantly reduced extracellular bactericidal activity,
while apparently retaining significant intracellular toxicity.
Bacteria resistant to the extracellular activity of melittin
remained sensitive to the intracellular toxicity when peptides
were internalized by electroporation, but were still measurably
less sensitive to the intracellular activity of melittin or mel12−26
than wild-type bacteria. It can be hypothesized that this
observation may also reflect some developed protection against
internal toxic effects. Prolonged exposure to these AMPs may
induce, or select for, mutations that enhance intracellular
protection against melittin, or activate facultative protective
mechanisms such as eﬄux pumps and peptidases. Previous
studies (Hsu et al., 2005; Marchand et al., 2006) have shown
that indolicidin can inhibit mRNA transcription by covalent
bonding at specific DNA sequences. Although the intracellular
targets of melittin have not yet been identified, the cationic charge
and leucine zipper motifs of melittin may cause non-specific
binding to nucleic acids (McCormick et al., 1996; Pavia et al.,
2012).
Previous studies have shown that permeabilization of artificial
membrane vesicles by three different lipo-peptide antibiotics
(Patel et al., 2014) and the toxicity of oxacillin for MRSA
(Komatsuzawa et al., 1995) were increased in the presence of
a non-ionic detergent. Our study has shown a similar increase
in the antibacterial activities of mel12−26, melittin, and bac8c
against wild-type MRSA with increasing concentrations of Triton
X-100. This suggests either that permeabilization of the bacterial
outer membrane facilitates access for peptides to intracellular
targets, or that the detergent enhances membrane instability. The
relatively small increase in bactericidal activity of melittin and
bac8c in the presence of Triton X-100 may reflect strong existing
membrane penetrating forces that make the effects of other
permeabilizing agents only marginal. The presence of Triton
X-100 did not increase the bactericidal efficacy of melittin or
mel12−26 against resistant bacteria. It is possible that outer
surface modifications on resistant bacteria may reduce the cells’
sensitivity to other membrane permeabilizing agents, as shown
in Salmonella enterica by McKelvey et al. (2014).
The relatively rapid gain and loss of peptide resistance
described here is in stark contrast to the reported dynamics of
antibiotic resistance stability over time (Andersson and Hughes,
2011). Our results suggest that the capability for development
of resistance to an AMP may not preclude its therapeutic use
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in strategically designed regimens. Furthermore, the antibacterial
efficacy of AMPs may be enhanced by combining them with
membrane-surfactants.
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